Associazione Conoscere Eurasia, Italian partner of the Roscongress Foundation, together with the Embassy of the Republic of Italy in Russian Federation intend to assist Sputnik V get certified in Italy. Sputnik V, Russian adenoviral vector vaccine has been designed by the National Research Center for Epidemiology and Microbiology named after Honorary Academician Gamaleya of the Ministry of Health of the Russian Federation.
Antonio Fallico, President of the Associazione Conoscere Eurasia and Chairman of the Board of Directors, Banca Intesa, shared with Telenuovo that in November, together with the members of his family, he received the Russian vaccine and none of them reported any considerable side effects. According to Professor Fallico, it is in Europe’s best interest to receive Russian vaccine for mass roll out on the continent.
“Sputnik V has been registered in Russia in August 2020. Prior to registration, it has been tested on roughly 700,000 people. Testing went well: the vaccine demonstrated high efficiency and lack of pathologically grave side effects. Mass vaccination campaign in Russia launched on 5 December. Italian scientists also confirm reliability of Sputnik V,” said Mr. Fallico.
Currently, the number of required doses and financial support is being discussed with the Italian Ministry of Health. Associazione intends to actively promote Sputnik V on other European markets.
Sputnik V was the first registered vaccine against SARS-CoV-2 in the world. The vaccine is produced using a unique approach involving the use of two different types of vectors based on human adenovirus, which makes it possible to enhance the immune response and form long-term immunity. The efficacy of the Russian vaccine is over 90 per cent. This approach has already been adopted by global pharmaceutical manufacturers. Namely, AstraZeneca will begin a clinical trial of its vaccine in combination with the adenovirus vector of the Sputnik V to improve the effectiveness of its own vaccine through the combined approach.